Sun Pharma announced the launch of Infugem (gemcitabine in sodium chloride injection) 10mg/mL for intravenous (IV) use in a ready-to-administer (RTA) bag.
Infugem is an alcohol-free, premixed, ready-to-infuse formulation indicated in combination with carboplatin to treat advanced ovarian cancer, in combination with paclitaxel to treat metastatic breast cancer, in combination with cisplatin to treat non-small cell lung cancer, and as a single agent to treat pancreatic cancer. Selection of the appropriate Infugem premixed bag for infusion is based on indication and patient’s body surface area (BSA).
The product is stable when stored at room temperature for 2 years compared with other gemcitabine products that require reconstitution and/or dilution and are only stable at room temperature for 24 hours.
“The availability of gemcitabine in ready-to-infuse bags is a welcome development, simplifying the complex delivery of this vital chemotherapy medication,” commented Jeff Lombardo PharmD, BCOP, Research Assistant Professor, Center of Integrated Global Biomedical Sciences, University at Buffalo.
Infugem is supplied as 1200mg/120mL, 1300mg/130mL, 1400mg/140mL, 1500mg/150mL, 1600mg/160mL, 1700mg/170mL, 1800mg/180mL, 1900mg/190mL, 2000mg/200mL, and 2200mg/220mL single-dose infusion bags.
For more information call (800) 818-4555 or visit Infugem.com.